Metallothionein inhibits ischemia-reperfusion injury in mouse heart

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 276, Issue 3 45-3, 1999, Pages

  Kang, Y James ^a   Li, Guangqiu ^a   Saari, Jack T ^b  

^a University of Louisville School of Medicine   (United States)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

Contractile force; Creatine kinase; Infarction; Langendorff; Myocardium

Indexed keywords

CREATINE KINASE; METALLOTHIONEIN;

ANIMAL EXPERIMENT; ARTICLE; ENZYME RELEASE; FEMALE; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TRANSGENIC MOUSE;

EID: 0032955692     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1999.276.3.h993     Document Type: Article

References (29)

1. Abel, J., and N. de Ruiter. Inhibition of hydroxyl-radical-generated DNA degradation by metallothionein. Toxicol. Lett. 47: 191-196, 1989.
2. Allen, C. B., and J. T. Saari. Isolated hearts from copper-deficient rats exhibit improved postischemic contractile performance. J. Nutr. 123: 1794-1800, 1993.
3. Becker, L. C., and G. Ambrosio. Myocardial consequences of reperfusion. Prog. Cardiovasc. Dis. 30: 23-44, 1987.
4. Bolli, R., M. O. Jeroudi, B. S. Patel, O. I. Aruoma, B. Halliwell, E. K. Lai, and P. B. McCay. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ. Res. 65: 607-622, 1989.
5. Bresnahan, G. F., R. Roberts, W. E. Shell, J. Ross, Jr., and B. E. Sobel. Deleterious effects due to hemorrhage after myocardial reperfusion. Am. J. Cardiol. 33: 82-86, 1974.
6. Eaton, D. L., and M. G. Cherian. Determination of metallothionein in tissues by cadmium-hemoglobin affinity assay. Methods Enzymol. 205: 83-88, 1991.
7. Eddy, L. J., D. V. Goeddel, and G. H. Wong. Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem. Biophys. Res. Commun. 184: 1056-1059, 1992.
8. Gross, G. J., N. E. Farber, H. F. Hardman, and D. C. Warltier. Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am. J. Physiol. 250 (Heart Circ. Physiol. 19): H372-H377, 1986.
9. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329: 673-682, 1993.
10. Hamer, D. H. Metallothionein. Annu. Rev. Biochem. 55: 913-951, 1986.
11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2: 349-360, 1988.
12. Kagi, J. H. R. Overview of metallothionein. Methods Enzymol. 205: 613-626, 1991.
13. Kang, Y. J., Y. Chen, and P. N. Epstein. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J. Biol. Chem. 271: 12610-12616, 1996.
14. Kang, Y. J., Y. Chen, A. Yu, M. Voss-McCowan, and P. N. Epstein. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J. Clin. Invest. 100: 1501-1506, 1997.
15. Li, G., Y. Chen, J. T. Saari, and Y. J. Kang. Catalase overexpressing transgenic mouse heart is resistant to ischemia-reperfusion injury. Am. J. Physiol. 273 (Heart Circ. Physiol. 42): H1090-H1095, 1997.
16. Ludbrook, J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res. 28: 303-311, 1994.
17. Manning, A. S., D. J. Coltart, and D. J. Hearse. Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ. Res. 55: 544-548, 1984.
18. McCord, J. M. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 312: 159-163, 1985.
19. Naganuma, A., M. Satoh, and N. Imura. Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice. Jpn. J. Cancer Res. 19: 406-411, 1988.
20. Namikawa, K., Y. Okazaki, S. Nishida, S. Kimoto, F. Akai, T. Tomura, and S. Hashimoto. Changes in myocardial metallothionein on isoproterenol-induced myocardial injury. J. Pharmaceut. Soc. Japan 113: 591-595, 1993.
21. Oliver, I. T. A spectrophotometric method for the determination of creatine kinase. J. Lab. Clin. Med. 62: 159-164, 1963.
22. Opie, L. H. Reperfusion injury and its pharmacologic modification. Circulation 80: 1049-1062, 1989.
23. Poltronieri, R., A. Cevese, and A. Sbarbati. Protective effect of selenium in cardiac ischemia and reperfusion. Cardioscience 3: 155-160, 1992.
24. Satoh, M., A. Naganuma, and N. Imura. Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination. Cancer Chemother. Pharmacol. 21: 176-178, 1988.
25. Satoh, M., M. Sasaki, and H. Hojo. Tissue specific induction of metallothionein synthesis by tumor necrosis factor-alpha. Res. Commun. Chem. Pathol. Pharmacol. 75: 159-172, 1992.
26. Tamura, Y., L. Chi, E. J. Driscoll, Jr., P. T. Hott, B. M. Freeman, K. P. Gallagher, and B. R. Lucchesi. Superoxide dismutase conjugated to polyethylene glycol provides sustained protection against myocardial ischemia/reperfusion injury in canine heart. Circ. Res. 63: 944-959, 1988.
27. Templeton, D. M., and M. G. Cherian. Toxicological significance of metallothionein. Methods Enzymol. 205: 11-24, 1991.
28. Thomas, J. P., G. L. Bachowski, and A. W. Girotti. Inhibition of cell membrane lipid peroxidation by cadmium- and zinc-metallothionein. Biochim. Biophys. Acta 884: 448-461, 1986.
29. Thornalley, P. J., and M. Vasak. Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim. Biophys. Acta 827: 36-44, 1985.